Not Yet RecruitingNot Applicable

Blink Reminders and Meibomian Gland Loss in Digital Screen Users

28 participantsStarted 2026-02-19

Plain-language summary

This randomized clinical trial aims to evaluate if a blink reminder program ('BlinkEasy') reduces the progression of Meibomian gland loss in intensive digital screen users over three months , using infrared meibography as the primary structural measure. Additionally, the study will analyze changes in dry eye symptoms using the 12-item Ocular Surface Disease Index (OSDI) questionnaire and non-invasive tear break-up time (NIBUT).

Who can participate

Age range

18 Years – 40 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Participants aged 18 to 40 years. * Intensive digital screen users, defined as an average screen time of ≥4 hours per day for at least 3 days per week. * Ocular Surface Disease Index (OSDI) score ≥13 (indicating mild to severe symptoms). * Non-invasive tear break-up time (NIBUT) ≤10 seconds measured by infrared meibography. * Presence of visible Meibomian glands on baseline meibography, allowing for quantitative analysis. * Technical ability to install and operate the BlinkEasy software on their primary digital device. Exclusion Criteria: * Active ocular disease, including infections, corneal ulcers, or acute conjunctivitis. * History of ocular surgery (e.g., refractive surgery, cataract extraction) or significant ocular injury. * Use of topical ophthalmic medications affecting the ocular surface (e.g., steroids, glaucoma medications, or cyclosporine) within the last 3 months. * Active use of contact lenses that cannot be suspended for the duration of the 12-week study period. * Systemic conditions known to affect the ocular surface (e.g., Sjögren's syndrome, Rheumatoid Arthritis). * Diagnosis of Diabetes Mellitus (Type 1 or Type 2).

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Change from Baseline in Meibomian Gland Dropout Area and Meiboscore.

Timeframe: Baseline, 4 weeks, 8 weeks, and 12 weeks.

Trial details

NCT IDNCT07430137

SponsorAsociación para Evitar la Ceguera en México

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-06

Contact for this trial

José Francisco Heredia González, MD

52 + 5513095969 heredia.04102001@gmail.com

View on ClinicalTrials.gov More Dry Eye Syndromes trials